MRNA-1273 SARS-COV-2

MRNA-1273 SARS-COV-2 Uses, Dosage, Side Effects, Food Interaction and all others data.

The MRNA-1273 SARS-COV-2 (mRNA-1273) is a novel mRNA-based vaccine encapsulated in a lipid nanoparticle that encodes for a full-length pre-fusion stabilized spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by the novel coronavirus, SARS-CoV-2, leading to a respiratory illness alongside other complications. COVID-19 has high interpatient variability in symptoms, ranging from mild symptoms to severe illness. A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29). This trial was later followed by phase II and III trials, where the MRNA-1273 SARS-COV-2 demonstrated vaccine efficacy of 94.1%.

On December 18, 2020, the FDA issued an emergency use authorization (EUA) for the MRNA-1273 SARS-COV-2 as the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2 in patients aged 18 years and older, after the EUA issued for the Pfizer-BioNTech Covid-19 Vaccine on December 11, 2020. The MRNA-1273 SARS-COV-2 is administered as a series of two intramuscular injections, one month (28 days) apart. In clinical trials, there were no differences in the safety profiles between younger and older (65 years of age and older) study participants; however, the safety and effectiveness of the MRNA-1273 SARS-COV-2 have not been assessed in persons less than 18 years of age. On December 23, 2020, Health Canada issued an expedited authorization for the MRNA-1273 SARS-COV-2.

The MRNA-1273 SARS-COV-2 contains nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus. It has the potential to elicit a highly S-protein specific antiviral response. In clinical trials, the MRNA-1273 SARS-COV-2 demonstrated vaccine efficacy of 94.1%; however, the manufacturing company emphasizes that the vaccine may not protect all vaccine recipients against COVID-19, as some vaccinated patients still contracted the virus.

MRNA-1273 SARS-COV-2
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	MRNA-1273 SARS-COV-2
Generic	Moderna COVID-19 Vaccine
Moderna COVID-19 Vaccine Other Names	MRNA-1273 SARS-COV-2
Type
Protein binding	There is limited pharmacokinetic information.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

MRNA-1273 SARS-COV-2 is an mRNA vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, in patients aged 18 years and older.

The MRNA-1273 SARS-COV-2 is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. It is administered in two doses, one month (28 days) apart.

MRNA-1273 SARS-COV-2 is also used to associated treatment for these conditions: Coronavirus Disease 2019 (COVID‑19)

How MRNA-1273 SARS-COV-2 works

The MRNA-1273 SARS-COV-2 is a vaccine that contains synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in Lipid nanoparticle (LNP) which codes for the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2. The S glycoprotein is a large transmembrane protein that plays a critical role in viral attachment, fusion, and entry into the host cell. Upon vaccination, human cells express the SARS-CoV-2 S antigen and immune response to the S antigen is elicited, leading to the protection against SARS-CoV-2.